Evaluation of the Safety and Usability of the MAK Exoskeleton in Patients With Stroke

Sponsor
MarsiBionics (Industry)
Overall Status
Completed
CT.gov ID
NCT04837144
Collaborator
(none)
6
1
1
8.5
0.7

Study Details

Study Description

Brief Summary

This study aims to evaluate the safety and usability of a motorized mobility assistance exoskeleton (MAK). The procedure explores the use of the MAK exoskeleton during the static and dynamic rehabilitation sessions with the intention to evaluate the safety and usability of the device in the studied population. The protocol has been focused on defining how the device can be used appropriately in this population in a safe manner by rehabilitation specialists.The study also aims to assess the safety of clinicians implementing the intervention, as well as possible benefits derived from the use of the device. As a secondary outcome, efficacy measurements will be collected.

Condition or Disease Intervention/Treatment Phase
  • Device: Physical Rehabilitation with MAK exoskeleton
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
6 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of the Safety and Usability of the MAK Exoskeleton in Patients With Stroke
Actual Study Start Date :
Oct 6, 2020
Actual Primary Completion Date :
Apr 30, 2021
Actual Study Completion Date :
Jun 23, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Group

The Intervention Group will receive 9 physical rehabilitation sessions using the MAK device. Each session will consist of approximately 90 minutes.

Device: Physical Rehabilitation with MAK exoskeleton
The participants will assist to 9 physical rehabilitation sessions with the MAK exoskeleton. During these sessions, different movements and therapies will be conducted using the studied device.

Outcome Measures

Primary Outcome Measures

  1. Safety as number of serious device adverse events [after each use of exoskeleton, for 5 weeks]

    Presence of a serious device adverse events where the participant or therapist is involved

Secondary Outcome Measures

  1. Safety as presence of adverse events or adverse device events [after each use of exoskeleton, for 5 weeks]

    Presence of a device adverse events where the participant or therapist is involved

  2. Exercises [measured as time per exercise in seconds] [after each use of exoskeleton, for 5 weeks]

    Measured as time per event at each therapy session

  3. Transfers [measured as time to carry out the transfers in seconds] [At each use of exoskeleton, for 5 weeks]

    Measured as time and level of assistance to carry out the transfers

  4. Acceptability [number of participants which discontinue the participation during the trial in relation with the included participants] [at the end of the 5th week]

    Measured as abandon ratio

  5. Accessibility [number of potential participants in relation with the included participants] [at the end of the 5th week]

    Measured as relation between number of participants and number of potential participants which weren't recruited

  6. Fall Prevalence [number of falls during the using of the device] [During the use of the device, for 5 weeks]

    Number of falling events ocurred from the participant or therapist

  7. Skin integrity [number of skin injuries related to the device] [before and after each use of exoskeleton, for 5 weeks]

    skin integrity measured as the number of skin injuries

  8. Pain [VAS scale] [Before and after the use of the device, during 5 weeks]

    Pain registered before and after the use of the device, by the participant and therapist

  9. Fatigue [Borg Scale] [Before and after the use of the device, during 5 weeks]

    Fatigue registered before and after the use of the device, by the participant and therapist

  10. Spasticity [Modified Ashworth Scale] [Before and after the use of the device, during 5 weeks]

    Spasticity registered before and after the use of the device

  11. Heart rate [measured with sphygmomanometer] [Before and after the use of the device, during 5 weeks]

    Number of heart beats per minute

  12. Physical evaluation [number of physical injuries detected] [Before and after the use of the device, during 5 weeks]

    Physical Evaluation as presence of tissue damage

  13. Muscle Strength [measured with Hand Held Dynamometer in N] [At the first day, 3rd week and 5th week]

    Muscle Strength measured at hip, knee and ankle muscles

  14. ROM [measured with goniometer] [At the first day, 3rd week and 5th week]

    Range of Movement

  15. Functional Mobility [Functional Ambulation Category scale] [At the first day, 3rd week and 5th week]

    Functional Mobility with and without the device

  16. System Usability [System Usability Scale] [At the 5th week]

    Measurement of System's Usability measured by the therapist

  17. User perception of the device [QUEST 2.0] [At the 5th week]

    QUEST 2.0 will be assessed by the therapist and participant

  18. Distance covered walking [6MWT] [At the first day, 3rd week and 5th week]

    6MWT recorded using the device

  19. Device malfunction [as number and type of device malfunction] [During the use of the device, for 5 weeks]

    Any device malfunction will be recorded

  20. Particpant's stability [TUG] [At the first day, 3rd week and 5th week]

    Timed Up and Go Scale

  21. Breath Rate [Breathings per minute] [Before and after the use of the device, during 5 weeks]

    Number of breaths per 1 minute

  22. SP/DP [sphygmomanometer] [Before and after the use of the device, during 5 weeks]

    Systolic and Diastolic Pressure measured in mmHg

  23. SpO2 [pulse oximeter] [Before and after the use of the device, during 5 weeks]

    SpO2 measured in %

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age between 18 and 85 years

  • Weight < 100 kg

  • Height between 1.5 and 1.9 meters

  • Anthropometric measurements to fit in the exoskeleton:

  • Distance from the center of the knee joint to the ground: 42 - 55 cm

  • Distance from the center of the knee to the groin fold: more than 28 cm.

  • Perimeter in thigh (midpoint trochanter - epicondyle): 40 - 63 cm.

  • Perimeter in calf (point of greater volume): 30 - 44 cm.

  • Ability to follow simple commands and communicate basic needs

  • Presence of unilateral hemiparesis

  • Diagnosis of stroke confirmed with imaging tests.

  • Sub-acute or chronic patients (time since diagnosis 1 month or more)

  • Score on FAC scale from 1 to 4

  • Sufficient postural control to maintain standing posture and to take a step with the weight on the affected lower limb, manual assistance or technical aids being allowed

Exclusion Criteria:
  • Spasticity > 3 in lower limbs according to the MAS scale

  • Skin alterations in the contact areas with the exoskeleton

  • Planned surgical intervention during the duration of the study

  • Two or more osteoporotic fractures in the lower limbs in the last 2 years

  • Presence of other pathologies that cause exercise intolerance (such as uncontrolled hypertension, coronary artery disease, arrhythmia, congestive heart failure, Parkinson's, severe lung disease)

  • Surgical operation in the 3 months prior to the start of the study on the lower limbs

Contacts and Locations

Locations

Site City State Country Postal Code
1 MarsiCare Madrid Arganda Del Rey Spain 28500

Sponsors and Collaborators

  • MarsiBionics

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
MarsiBionics
ClinicalTrials.gov Identifier:
NCT04837144
Other Study ID Numbers:
  • MAKStrokeUSII
First Posted:
Apr 8, 2021
Last Update Posted:
Jun 24, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by MarsiBionics
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 24, 2021